Literature DB >> 29704257

Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened.

Sumera Rizvi1, Gregory J Gores1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29704257      PMCID: PMC6204118          DOI: 10.1002/hep.30069

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Authors:  Milind Javle; Maeve Lowery; Rachna T Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J Borad; Ramesh K Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do-Youn Oh; Philip A Philip; Li-Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun-Huei Yeh; Kristen Ciombor; Richard S Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X Zhu; Ghassan K Abou-Alfa; Tanios Bekaii-Saab
Journal:  J Clin Oncol       Date:  2017-11-28       Impact factor: 44.544

2.  Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.

Authors:  Li Tan; Jun Wang; Junko Tanizaki; Zhifeng Huang; Amir R Aref; Maria Rusan; Su-Jie Zhu; Yiyun Zhang; Dalia Ercan; Rachel G Liao; Marzia Capelletti; Wenjun Zhou; Wooyoung Hur; NamDoo Kim; Taebo Sim; Suzanne Gaudet; David A Barbie; Jing-Ruey Joanna Yeh; Cai-Hong Yun; Peter S Hammerman; Moosa Mohammadi; Pasi A Jänne; Nathanael S Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

Review 3.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

4.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Authors:  Lucia Nogova; Lecia V Sequist; Jose Manuel Perez Garcia; Fabrice Andre; Jean-Pierre Delord; Manuel Hidalgo; Jan H M Schellens; Philippe A Cassier; D Ross Camidge; Martin Schuler; Ulka Vaishampayan; Howard Burris; G Gary Tian; Mario Campone; Zev A Wainberg; Wan-Teck Lim; Patricia LoRusso; Geoffrey I Shapiro; Katie Parker; Xueying Chen; Somesh Choudhury; Francois Ringeisen; Diana Graus-Porta; Dale Porter; Randi Isaacs; Reinhard Buettner; Jürgen Wolf
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

5.  Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Authors:  Lipika Goyal; Supriya K Saha; Leah Y Liu; Giulia Siravegna; Ignaty Leshchiner; Leanne G Ahronian; Jochen K Lennerz; Phuong Vu; Vikram Deshpande; Avinash Kambadakone; Benedetta Mussolin; Stephanie Reyes; Laura Henderson; Jiaoyuan Elisabeth Sun; Emily E Van Seventer; Joseph M Gurski; Sabrina Baltschukat; Barbara Schacher-Engstler; Louise Barys; Christelle Stamm; Pascal Furet; David P Ryan; James R Stone; A John Iafrate; Gad Getz; Diana Graus Porta; Ralph Tiedt; Alberto Bardelli; Dejan Juric; Ryan B Corcoran; Nabeel Bardeesy; Andrew X Zhu
Journal:  Cancer Discov       Date:  2016-12-29       Impact factor: 39.397

6.  Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.

Authors:  Rondell P Graham; Emily G Barr Fritcher; Ekaterina Pestova; John Schulz; Leonid A Sitailo; George Vasmatzis; Stephen J Murphy; Robert R McWilliams; Steven N Hart; Kevin C Halling; Lewis R Roberts; Gregory J Gores; Fergus J Couch; Lizhi Zhang; Mitesh J Borad; Benjamin R Kipp
Journal:  Hum Pathol       Date:  2014-04-13       Impact factor: 3.466

7.  Identification of targetable FGFR gene fusions in diverse cancers.

Authors:  Yi-Mi Wu; Fengyun Su; Shanker Kalyana-Sundaram; Nickolay Khazanov; Bushra Ateeq; Xuhong Cao; Robert J Lonigro; Pankaj Vats; Rui Wang; Su-Fang Lin; Ann-Joy Cheng; Lakshmi P Kunju; Javed Siddiqui; Scott A Tomlins; Peter Wyngaard; Seth Sadis; Sameek Roychowdhury; Maha H Hussain; Felix Y Feng; Mark M Zalupski; Moshe Talpaz; Kenneth J Pienta; Daniel R Rhodes; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2013-04-04       Impact factor: 39.397

  7 in total
  1 in total

1.  Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors.

Authors:  Fangda Li; April N Meyer; Malalage N Peiris; Katelyn N Nelson; Daniel J Donoghue
Journal:  Transl Oncol       Date:  2020-08-24       Impact factor: 4.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.